跳至主要内容
临床试验/ISRCTN54139009
ISRCTN54139009进行中(未招募)Unknown

A randomized controlled study to evaluate a digital intervention for the treatment of unipolar depression in adults

Elona Health GmbH0 个研究点目标入组 158 人开始时间: 2023年7月6日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方
入组人数
158

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • All subjects must have been diagnosed with one of the following ICD-10 diagnoses:
  • F32.0: Mild depressive episode
  • F32.1: Moderate depressive episode
  • F32.2: Severe depressive episode
  • F33.0: Recurrent depressive disorder, current episode mild
  • F33.1: Recurrent depressive disorder, current episode moderate
  • F33.2: Recurrent depressive disorder, current episode severe
  • Subjects further need to:
  • 1. Be at least 18 years old
  • 2. Possess sufficient German language skills (in writing and reading)
  • 3. Possess a smartphone (iOS or Android operating system) with internet access
  • 4. Provide signed and dated informed consent and be willing to comply with the protocol

排除标准

  • All subjects without the inclusion ICD-10 diagnosis criteria, as well as subjects with the following ICD-10 diagnoses, are excluded:
  • F00-F09: Organic, including symptomatic, mental disorders
  • F10-F19 Mental and behavioural disorders due to psychoactive substance use (except F17.1, F17.2, F17.3)
  • F20-F29: Schizophrenia, schizotypal and delusional disorders
  • F30: Manic episode
  • F31.0, F31.1, F31.2, F31.5, F31.6, F31.8, F31.9: Bipolar disorder current hypomanic or manic episode
  • F32.3: Severe depressive episode with psychotic symptoms
  • F33.3: Recurrent depressive disorder, current episode severe with psychotic symptoms
  • 1. Subjects with acute suicidality (assessed via suicidality screening of the mini-DIPS at the initial screening)
  • 2. Subjects under the age of 18 years
  • 3. Subjects without any access to a smartphone (iOS or Android operating system) with internet access
  • 4. Subjects without German language proficiency
  • If a subject is currently enrolled or is planning to participate in a potentially confounding drug or device trial during the study, enrollment into this study needs to be pre-approved by the principal investigator

研究者

发起方
Elona Health GmbH

相似试验